Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

treatment arm, and none have been reported during the treatment

extension.

* Twenty-four out of 26 patients demonstrated an increase in a-GAL as

measured in white blood cells, kidney, and skin.

* a-GAL increases were seen in patients with both low levels of residual

enzyme activity (<3%) at baseline as well as patients presenting with

higher baseline levels (greater than or equal to 3%).

* Kidney GL-3 levels as measured in urine or biopsies were decreased in

patients who demonstrated greater increases in levels of a-GAL.

* Renal and cardiac function results were encouraging, including those

seen in patients treated for nearly two years.

* Patient responses were consistent with the results of in vitro testing

of Fabry mutations, thus improving the ability to select likely

responders for future studies.

"These data demonstrate that Amigal has a meaningful effect on a range of genetic mutations in Fabry disease and thus has the potential to treat a significant portion of the Fabry patient population," said William Wilcox, M.D., Ph.D., Director of the Metabolic Disorders Clinic at Cedars-Sinai Medical Center and a principal investigator in one of the Amigal clinical trials.

Amicus expects that the results will be presented again at the American College of Medical Genetics (ACMG) Annual Meeting on March 12-16, 2008, in Phoenix, Arizona.

Based on the results of these Phase 2 trials, Amicus and Shire plan to meet with US and European regulatory authorities to discuss the design of a Phase 3 clinical trial for Amigal.

About Fabry Disease

Fabry disease is a lysosomal storage disorder caused by inherited genetic mutations in the GLA gene, which result in deficient activity of the enzyme alpha-galactosidase A (a-GAL). Deficient a-GAL activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the various s
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Semiconductor industry leader ... Light-based Technologies (IYL 2015) visionary John Dudley were ... the international society for optics and photonics , last ... and Dudley along with other awards announced earlier this ... by James Harrington, during a gala banquet Wednesday evening ...
(Date:9/2/2014)... detailed studies of what happens on the surface of ... other applications. A group of researchers from Lund University ... form across a large number of vertical nanowires, known ... of a cell and its surroundings takes place through ... that holds the cell together and that largely comprises ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... Lumiphore, Inc., a,biotechnology leader in the ... use in high-value applications, announced,that it has ... Inc.,Redwood City, California to apply Lumiphore products ... Under the agreement, Biophor Diagnostics holds the ...
... Inc. (OTC,Bulletin Board: NZYM) announced today the appointment ... on October 1, 2008. Since May,2008, Dr. Farkas ... over 13 years, experience with amino acid derivatives, ... and supply chain,management at Bachem Corporation, Novartis AG ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer ... Chief Executive Officer,and Robert S. Brown, Chief Financial Officer, ... on October 6, 2008 at Le Parker,Meridien Hotel in ... Monday, October 6th at,2:30 p.m. ET. To listen to ...
Cached Biology Technology:Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2Synthetech Announces New Director of Manufacturing 2NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2
(Date:9/2/2014)... truth; everyone has a tipping point. We all want to ... benefit is great enough. Now, scientists have confirmed the area ... , The result was published online this week in ... honest, even if lying is beneficial," said Lusha Zhu, the ... Virginia Tech Carilion Research Institute , where she works with ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... the U.S. diet showed some modest improvement in the ... in the consumption of unhealthy trans fats, but the ... and the poor. , , An unhealthy diet is ... Eating a healthy diet is an important part of ... trends in diet quality is important because it can ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rh&#244;ne Valley 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... its prestigious Clinical and Translational Science Award (CTSA) ... the amount of $29 million over the next ... wireless technology and bioinformatics toward individualizing medicine. ... Health and The Scripps Research Institute in partnership ...
... 22, 2013 More accurate and precise assessment of ... a particular gene that are present in a genome, ... cancer and other diseases including autoimmune disorders. However, ... labor intensive, or prohibitively costly, diminishing their effectiveness in ...
... New research shows that in sub-Saharan Africa the virus responsible ... distances and the African buffalo are important natural reservoirs for ... online open-access journal of the American Society for Microbiology, sheds ... 2 emerged in sub-Saharan Africa and identifies patterns of spread ...
Cached Biology News:NIH awards Scripps Translational Science Institute $29 million grant 2NIH awards Scripps Translational Science Institute $29 million grant 3Bio-Rad's Droplet Digital PCR technology highlighted at ASHG Annual Meeting 2Foot and mouth disease in sub-Saharan Africa moves over short distances, wild buffalo are a problem 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
...
Biology Products: